Johnson & Johnson announced positive Phase 3 results from the MajesTEC-9 study, showing TECVAYLI (teclistamab-cqyv) significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients treated as early as second line. TECVAYLI reduced disease progression or death risk by 71% and death risk by 40%, with nearly two-thirds achieving complete response or better. The study supports TECVAYLI's potential as a new standard of care, with regulatory submissions underway in the US and Europe.
Johnson & Johnson's Phase 3 PROTEUS study shows ERLEADA (apalutamide) combined with hormone therapy before and after surgery significantly improves outcomes for high-risk localized prostate cancer patients. The treatment increased the chance of minim...
Johnson & Johnson reported that subcutaneous amivantamab, a dual EGFR and MET inhibitor, achieved a 42% overall response rate in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. More...
Johnson & Johnson's Phase 3 PROTEUS study found that combining apalutamide with hormone therapy before and after prostate cancer surgery significantly improves outcomes for high-risk localized or locally advanced prostate cancer patients. The treatme...
Johnson & Johnson announced that their drug combination RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGF...
Johnson & Johnson announced FDA approval for an updated label on TREMFYA (guselkumab), highlighting its ability to inhibit structural joint damage progression in adults with active psoriatic arthritis (PsA). This update is based on positive 24-week P...
